Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

OBJECTIVE: Long-term treatment with up to 1.8 mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investigation in subjects without diabetes. Aim of our study was to investigate whether h...

Descripción completa

Detalles Bibliográficos
Autores principales: Peradze, Natia, Farr, Olivia M., Perakakis, Nikolaos, Lázaro, Iolanda, Sala-Vila, Aleix, Mantzoros, Christos S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823961/
https://www.ncbi.nlm.nih.gov/pubmed/31672146
http://dx.doi.org/10.1186/s12933-019-0945-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823961/
https://www.ncbi.nlm.nih.gov/pubmed/31672146
http://dx.doi.org/10.1186/s12933-019-0945-7

Ejemplares similares